Oligonucleotide (Antisense oligonucleotide) · Gene silencing: Methyl CpG Binding Protein 2 (MECP2) · developed by IONIS PHARMACEUTICALS
ION440 is an antisense oligonucleotide targeting MECP2 mRNA, administered by intrathecal injection. It is being studied in MECP2 Duplication Syndrome, a neurological disorder caused by duplication of the MECP2 gene.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06430385 | Phase 1/2 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Recruiting | IONS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.
See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IONS catalysts and pipeline →